Tarsus Pharmaceuticals, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2018 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Tarsus Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2018 to 2023.
  • Tarsus Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$23.4M, a 40.2% increase year-over-year.
  • Tarsus Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$134M, a 24.9% decline year-over-year.
  • Tarsus Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$136M, a 119% decline from 2022.
  • Tarsus Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$62.1M, a 349% decline from 2021.
  • Tarsus Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$13.8M, a 48.4% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$136M -$73.8M -119% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-27
2022 -$62.1M -$48.3M -349% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-27
2021 -$13.8M +$13M +48.4% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-17
2020 -$26.8M -$22.1M -474% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-14
2019 -$4.67M -$3.35M -254% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-31
2018 -$1.32M Jan 1, 2018 Dec 31, 2018 10-K 2021-03-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.